Friday, July 13, 2018 11:35:55 AM
10:49 am ET July 13, 2018 (Benzinga) Print
Two days after Cantor Fitzgerald gave Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) a shot in the arm with an ultrabullish rating, Stifel Nicolaus administered a booster.
Galmed spiked 15 percent Friday morning after already having risen 21 percent in the preceding session.
The Analyst
Stifel analyst Adam Walsh initiated coverage of Galmed with a Buy rating and $35 price target.
The Thesis
As with Cantor Fitzgerald, Galmed’s Aramchol was again the point of optimism.
Walsh considers the candidate a multibillion-dollar opportunity for the treatment of non-alcoholic steatohepatitis, or NASH, and forecast a “decent chance” of an Aramchol partnership deal materializing ahead of the Phase 3 trial launch in the first half of 2019. (See Walsh's track record here.)
“We think large-pharma validation could drive shares significantly higher,” the analyst said.
With positive Phase 2b results failing to stimulate the stock, Stifel said the Street overlooked Aramchol’s strengths and thereby created a buying opportunity.
Aramchol did not reach statistical significance on either of two approvable endpoints — but they were secondary endpoints and were not powered for statistics, Walsh said.
“While Aramchol did not hit statistical significance on either of the two approvable endpoints, we remind investors that these “Despite this, Aramchol nearly hit on NASH resolution without worsening of fibrosis and showed strong trends on the fibrosis improvement with no worsening of NASH.”
The analyst expects the next phase to generate the statistically significant data investors demand.
After conversations with management, Walsh rejected concerns over dropout rates and competition from Madrigal Pharmaceuticals Inc (NASDAQ: MDGL).
Price Action
Galmed shares were rallying 16.27 percent to $14.85 at the time of publication Friday morning.
Related Links:
Galmed Shares More Than Double As It Hits Bullseye With Fatty Liver Candidate
Zogenix Soars On Positive Phase 3 Data In Dravet Syndrome Study
Photo by Nephron/Wikimedia.
Latest Ratings for GLMD DateFirmActionFromTo
Jul 2018Stifel NicolausInitiates Coverage OnBuy Jul 2018Cantor FitzgeraldInitiates Coverage OnOverweight Jun 2018Maxim GroupMaintainsBuyBuy
New York Yankees and Duke Basketball
Recent GLMD News
- Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023 • PR Newswire (US) • 04/04/2024 09:06:00 PM
- Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis • PR Newswire (US) • 03/15/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:14:47 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 09:15:15 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/30/2023 05:15:10 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 11/22/2023 09:48:47 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/20/2023 09:37:19 PM
- Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study • PR Newswire (US) • 11/20/2023 09:32:00 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 11/01/2023 08:15:07 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/26/2023 12:51:11 PM
- Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis • PR Newswire (US) • 09/26/2023 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/22/2023 08:15:32 PM
- Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification • PR Newswire (US) • 09/22/2023 08:05:00 PM
- Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] • Edgar (US Regulatory) • 09/21/2023 11:30:15 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/20/2023 08:30:03 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/13/2023 08:01:23 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/09/2023 08:43:34 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/09/2023 08:30:34 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/02/2023 08:30:30 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 07/21/2023 02:12:35 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/18/2023 01:25:58 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 07/18/2023 01:23:52 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/14/2023 01:44:16 PM
- Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering • PR Newswire (US) • 07/14/2023 01:30:00 PM
- Form F-1/A - Registration statement for certain foreign private issuers: [Amend] • Edgar (US Regulatory) • 07/13/2023 09:08:25 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM